Evidence map›Paper›PMID 32681944›Full record

ArticleHuman pathology2020

Secondary renal neoplasia following chemotherapy or radiation in pediatric patients.

Sounak Gupta, Chad M Vanderbilt, Bradley C Leibovich, Loren Herrera-Hernandez, Aditya Raghunathan, William R Sukov, Jesse S Voss, Emily G Barr Fritcher, Katelyn A Reed, Christine M Lohse and 4 more

Open access · greenAbstract read
In one paragraph

Article in Human pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Sounak GuptaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: gupta.sounak@mayo.edu.
Chad M VanderbiltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. Electronic address: vanderbc@mskcc.org.
Bradley C LeibovichDepartment of Urology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: leibovich.bradley@mayo.edu.
Loren Herrera-HernandezDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: herrerahernandez.loren@mayo.edu.
Aditya RaghunathanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: raghunathan.aditya@mayo.edu.
William R SukovDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: sukov.william@mayo.edu.
Jesse S VossDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: voss.jesse@mayo.edu.
Emily G Barr FritcherDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: BarrFritcher.Emily@mayo.edu.
Katelyn A ReedDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: reed.katelyn@mayo.edu.
Christine M LohseDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: lohse.christine@mayo.edu.
Victor E ReuterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. Electronic address: reuterv@mskcc.org.
Rafael E JimenezDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: jimenez.rafael@mayo.edu.
R Houston ThompsonDepartment of Urology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: thompson.robert@mayo.edu.
John C ChevilleDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address: cheville.john@mayo.edu.
Mayo Clinic · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USMayo Clinic in Florida · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Renal neoplasia occurring as a second malignancy following childhood cancer has been most closely associated with neuroblastoma and Wilms tumor. While some cases have been associated with a genetic predisposition, nearly all are thought to result from "late effects" of therapy-related toxicity that involves chemotherapy or radiation. It is unclear if these tumors are enriched for specific molecular or morphologic characteristics. A query of our institutional nephrectomy registry of 8295 patients for renal neoplasia occurring post-treatment for childhood cancer revealed 6 patients with Wilms tumor, 4 with neuroblastoma, and 1 with acute lymphoblastic leukemia (ALL). Three additional cases of MiT family translocation renal cell carcinoma (RCC), from 2 patients, following chemotherapy for neuroblastoma and systemic lupus erythematosus and another of clear cell RCC post-ALL were included. The most common tumor type was clear cell RCC: 9/19 cases (47.4%), followed by metanephric adenoma and MiT family translocation RCC (3/19, 15.8%). There were no characteristic features to indicate a unique renal neoplasia subtype. Potential syndromic renal neoplasia occurred in 2 patients, metanephric adenomas and oncocytoma in a patient with hyperparathyroidism-jaw tumor syndrome post-treatment of Wilms tumor and a fumarate hydratase-deficient RCC in a patient post-treatment for ALL. The mean age at diagnosis of childhood neoplasia or treatment with chemotherapy or radiation was 4.7 years, and the average time to subsequent renal neoplasia was 31 years. Five (of 14) patients developed metastatic RCC, and there were 2 RCC-related deaths. These results indicate the need for extended clinical follow-up of these patients.

Indexed as

AdolescentAdultAntineoplastic AgentsChildChild, PreschoolFemaleHumansInfantKidney NeoplasmsMaleMiddle AgedNeoplasms, Second PrimaryRadiotherapyYoung AdultAntineoplastic AgentsChemotherapyNeuroblastomaRadiationRenal cell carcinomaWilms tumor

Identifiers

PMID32681944
PMCPMC8935764
OpenAlexW3043612581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.